Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.71%
1,092.80
-7.77
-0.71%
—1,100.571,098.941,103.801,084.24——
SIXC
Communications
SIXC
Communications
SIXC
-0.07%
604.74
-0.41
-0.07%
—605.15605.15606.69602.76——
SIXE
Energy
SIXE
Energy
SIXE
+1.64%
1,214.80
+19.61
+1.64%
—1,195.191,204.711,221.691,204.71——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.88%
1,724.57
-15.34
-0.88%
—1,739.911,734.501,734.501,710.67——
SIXM
Financials
SIXM
Financials
SIXM
+0.14%
639.43
+0.87
+0.14%
—638.56640.21645.32638.69——
SIXR
Staples
SIXR
Staples
SIXR
+0.91%
839.15
+7.58
+0.91%
—831.57840.48844.16834.54——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+1.06%
215.62
+2.26
+1.06%
—213.36213.36215.79212.77——
SIXT
Technology
SIXT
Technology
SIXT
-1.69%
3,179.52
-54.66
-1.69%
—3,234.183,171.863,195.363,145.46——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.13%
936.91
+1.26
+0.13%
—935.65937.31941.44933.16——
SIXV
Health care
SIXV
Health care
SIXV
+0.24%
1,452.77
+3.51
+0.24%
—1,449.261,454.771,462.651,447.95——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0.72%
2,365.18
-17.27
-0.72%
—2,382.452,371.192,380.452,362.86——
ORCHPHARMA:NSE
Orchid Pharma Ltd
₹618.00
+5.59%
(+32.70) 1D
Apr 29, 3:30:04 PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for ORCHPHARMA...
Open
₹588.25
High
₹624.80
Low
₹587.55
Mkt. cap
31.34B
Avg. vol.
65.88K
Volume
152.93K
P/E ratio
166.20
52-wk high
₹899.00
52-wk low
₹480.00
EPS
₹3.72
No. of employees
736
News stories
From sources across the web
Profile
Orchid Pharma Limited is an Indian pharmaceutical company based in Chennai. It was founded by Kailasam Raghavendra Rao on 1 July 1992. Orchid Pharma is the only pharma company in India to have discovered a New Drug Enmetazobactam which is now approved in United States, Europe and India. Wikipedia
About Orchid Pharma Ltd
CEO-
Employees736
Founded1992
Headquarters-
SectorPharmaceutical industry
Websiteorchidpharma.com
Last report
Feb 12, 2026
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-1.08/ (-0.30 est.)INR
-261.53%miss
Revenue / Estimate
2.07B/ (1.78B est.)INR
+16.31%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
2.37B
1.73B
1.94B
2.07B
Cost of goods sold
1.61B
988.65M
1.33B
1.43B
Cost of revenue
1.61B
988.65M
1.33B
1.43B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
241.18M
216.13M
248.51M
241.28M
Operating expense
570.92M
685.42M
713.95M
715.86M
Total operating expenses
2.18B
1.67B
2.04B
2.15B
Operating income
194.32M
55.21M
-103.77M
-74.65M
Other non operating income
-198.09M
114.48M
107.74M
56.09M
EBT including unusual items
222.55M
149.11M
-57.24M
-126.14M
EBT excluding unusual items
225.75M
149.11M
-57.24M
-55.01M
Income tax expense
-394.00K
-
-
-
Effective tax rate
-0.18%
-
-
-
Other operating expenses
241.02M
382.75M
376.43M
384.29M
Net income
222.95M
149.11M
-57.24M
-126.14M
Net profit margin
9.39%
8.62%
-2.96%
-6.09%
Earnings per share
4.40
-
-1.13
-1.08
Interest and investment income
172.77M
-
-
-
Interest expense
-39.15M
-32.58M
-37.32M
-31.78M
Net interest expenses
133.62M
-32.58M
-37.32M
-31.78M
Depreciation and amortization charges
88.72M
86.54M
89.01M
90.29M
EBITDA
279.42M
141.58M
-15.99M
10.45M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer